Waystar (WAY) Q2 2026: 40% of Bookings AI-Driven as Platform Consolidation Accelerates
AI-enabled solutions drove 40% of new bookings, solidifying Waystar’s shift toward autonomous revenue cycle management. Larger, multi-solution platform deals are compounding client value and expanding average contract size, while operational discipline and capital allocation support margin resilience. Rising capitalized software spend and embedded AI investments signal a decisive push to cement category leadership amid evolving payer-provider dynamics.
Summary
- Platform Consolidation Drives Larger Wins: Multi-module deployments are expanding average contract size and client stickiness.
- AI Monetization Embedded in Core Workflows: 40% of bookings are now AI-enabled, deepening product differentiation and driving cross-sell.
- Margin Strength Funds Long-Term Innovation: Elevated capitalized software spend and disciplined cost structure underpin ongoing investment in automation and AI.
Business Overview
Waystar is a healthcare payments technology company that provides revenue cycle management (RCM, software for automating healthcare billing and reimbursement) solutions to hospitals, health systems, and physician practices. The company generates revenue through a mix of subscription fees and transaction-based charges for its cloud-based platform, which connects providers and payers to streamline claims, payment, and reimbursement workflows. Its business is divided into subscription revenue (recurring SaaS contracts) and volume-based revenue (per-transaction fees), with ongoing expansion into AI-powered modules and cross-sell opportunities.
Performance Analysis
Waystar delivered 18% year-over-year revenue growth in Q2 2026, with organic revenue up 7% and normalized organic growth at 10%, reflecting robust execution and healthy demand across its platform. Subscription revenue grew at a double-digit pace and now constitutes 55% of total revenue, up from prior periods, as clients increasingly adopt multi-solution packages. Volume-based revenue, while up just 3% year-over-year, normalized to 8% growth after adjusting for large client implementations in the prior year, indicating a return to historical utilization trends after post-pandemic catch-up.
Adjusted EBITDA margin held at 43%, demonstrating the platform’s scalability and cost discipline even as the company ramps investments in AI and automation. Net revenue retention (NRR) remained strong at 108%, with gross revenue retention at 97%, underscoring both low churn and ongoing expansion within the client base. The company ended the quarter with $192 million in cash and short-term investments, and a net leverage ratio of 2.5x, well below its target ceiling.
- Subscription Revenue Outpaces Volume: Double-digit growth in SaaS contracts is shifting the revenue mix toward recurring, higher-margin streams.
- Large Client Wins Accelerate: The number of clients generating over $100,000 in trailing 12-month revenue grew 15% year-over-year, now at 1,453.
- AI-Driven Cross-Sell Momentum: More than $6 million in bookings from existing clients purchasing Iodine, clinical AI, capabilities highlight the platform’s expanding wallet share.
Capital allocation remains balanced between shareholder returns (stock buybacks) and aggressive investment in AI-powered product development, with capitalized software spend at the highest run rate in company history. Management raised both revenue and EBITDA guidance for the full year, reflecting confidence in pipeline conversion and operational leverage.
Executive Commentary
"Our AI deployment is not experimental. It is embedded and monetized, and it delivers meaningful outcomes inside the mission-critical workflows our clients rely on every day."
Matt Hawkins, Chief Executive Officer
"Adjusted EBITDA margin of 43% was consistent with the prior quarter and is indicative of the scalable nature of our platform model, disciplined cost management, and the favorable margin profile of the solutions driving growth across the business."
Steven Oreskovich, Chief Financial Officer
Strategic Positioning
1. Platform Consolidation and Client Expansion
Waystar is capitalizing on provider fatigue with fragmented point solutions, increasingly winning double-digit million-dollar annual contract value (ACV) deals that consolidate multiple legacy vendors into a single, integrated platform. This trend is driving both larger initial deals and higher net revenue retention as clients expand usage over time.
2. AI-First Revenue Cycle Automation
AI is now embedded and monetized across core workflows, with 40% of bookings in Q2 involving AI-enabled products, especially following the Iodine acquisition. These capabilities are driving measurable outcomes—such as $3 million in incremental revenue per 10,000 admissions for early adopters—and serve as a key differentiator versus both point solutions and EHR-native RCM modules.
3. Balanced Capital Allocation and Margin Discipline
Waystar is sustaining high margins (43% adjusted EBITDA) while stepping up capitalized software investment to accelerate AI product launches. The company is using its strong cash flow to fund both innovation and shareholder returns, with a new $200 million buyback program and continued deleveraging.
4. Secular Tailwinds from Payer-Provider Complexity
As regulatory and coverage dynamics create more uninsured and self-pay patients, demand for solutions that lower cost to collect and optimize reimbursement is rising. Waystar’s platform, which connects payers and providers at scale, is positioned as mission-critical infrastructure for navigating these headwinds.
5. Competitive Differentiation Versus EHR Vendors
Despite large EHR vendors pushing into RCM, Waystar’s system-of-action approach and best-of-breed outcomes are resonating with providers who prioritize ROI and operational results over “free” or bundled software. The company’s ability to integrate with over 500 EHRs and 200 channel partners further insulates it from displacement risk.
Key Considerations
Waystar’s Q2 2026 results reflect a business at the intersection of healthcare payments complexity and automation tailwinds. The company’s strategic bets on platform consolidation and AI are translating into larger, stickier client relationships and expanding addressable market. However, execution on large, multi-year deals and continued investment discipline will be critical as the industry landscape evolves.
Key Considerations:
- AI Monetization Now Embedded: 40% of all new bookings are AI-enabled, confirming that artificial intelligence is not just a feature but a core monetization engine.
- Client Expansion Drives Compounding Value: Net revenue retention remains robust as clients expand into new modules, supporting a durable growth algorithm.
- Capitalized Software Spend at Historic Highs: Elevated investment in R&D signals a race to build the most robust autonomous revenue cycle platform.
- Volume-Based Revenue Returns to Trend: Patient utilization growth has normalized to 1-2%, reducing the tailwind from post-pandemic catch-up.
Risks
Waystar faces risks from regulatory changes impacting payer mix, competitive encroachment by EHR vendors, and the execution complexity of large, multi-solution deployments. Rising capitalized software investment and AI compute costs require ongoing margin discipline, while client decision cycles for large platform deals remain lengthy (6-18 months). Any slowdown in healthcare utilization or delays in implementation could impact near-term growth and retention metrics.
Forward Outlook
For Q3 2026, Waystar guided to:
- Continued double-digit organic subscription revenue growth
- Adjusted EBITDA margin in the low 40% range
For full-year 2026, management raised guidance to:
- Revenue of $1.276 billion to $1.294 billion (midpoint up $2 million)
- Adjusted EBITDA of $535 million to $545 million (midpoint up $5 million)
Management highlighted several factors that will shape the second half:
- Robust pipeline of large RFPs, particularly for multi-module platform deals
- Ongoing investment in AI and automation, with some spend flowing through the P&L in H2
Takeaways
Waystar’s business model is compounding through platform consolidation and embedded AI, with margin strength funding aggressive innovation and capital returns. The company’s ability to win large, multi-solution deals and drive cross-sell into its base underpins a durable, high-growth trajectory, but execution discipline and competitive differentiation will be critical as the landscape shifts.
- AI-Driven Platform Expansion: Embedded AI is now a core driver of bookings and client outcomes, with measurable ROI for providers adopting new modules.
- Margin and Cash Flow Resilience: High free cash flow conversion and disciplined leverage enable Waystar to invest in innovation without sacrificing profitability.
- Future Watchpoint—Deal Conversion and Retention: Investors should monitor large deal ramp timelines, NRR stability, and the pace of AI monetization as competitive dynamics intensify.
Conclusion
Waystar’s Q2 2026 results confirm its evolution into an AI-first, platform-centric leader in healthcare revenue cycle management, with operational and financial discipline supporting both near-term growth and long-term innovation. Execution on large, multi-year deals and continued product differentiation will define the next phase of value creation.
Industry Read-Through
Waystar’s results underscore a secular shift toward platform consolidation and embedded AI across healthcare payments and revenue cycle management. Providers are increasingly seeking to reduce administrative complexity and cost by replacing fragmented point solutions with integrated platforms, a trend likely to pressure legacy vendors and single-point offerings. The rapid adoption of AI-enabled modules and the growing importance of monetized automation suggest that “AI as a feature” is giving way to “AI as a business model” across healthtech and enterprise SaaS. For peers and competitors, the message is clear: scale, data integration, and outcome-driven automation are becoming table stakes, and the winners will be those who can deliver measurable ROI and operational simplicity at enterprise scale.